Elucidating the role of API in the PI3K/AKT/p53 pathway provides a scientific foundation for future preclinical and clinical investigations intended to harness this natural compound for the targeted elimination of BCSCs and to improve patient outcomes in breast cancer treatment. Here, AKT1 is linked to breast carcinoma.